ENTITY
Samsung Biologics

Samsung Biologics (207940 KS)

331
Analysis
Health CareSouth Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
24 Nov 2022 14:42
Smartkarma Originals

APAC Healthcare Series (Part 4)- Japan Continues to Be in a Sweet Spot; Top Picks Quarterly Update

Japan healthcare companies with high export revenue, continue to benefit from favorable Fx. Three of our top picks reported strong quarterly...

Logo
511 Views
Share
bullishSamsung C&T
27 Oct 2022 02:39

Samsung C&T: Soundly Beat Consensus Operating Profit Estimates by 68% in 3Q 2022

Samsung C&T had outstanding results that soundly beat consensus estimates in 3Q 2022. Samsung C&T generated operating profit of 796.8 billion won...

Logo
152 Views
Share
bullishSamsung C&T
15 Oct 2022 15:54

Korean Holdcos Vs Opcos Gap Spreads Opportunities Amid Market Carnage

In this insight, we highlight the pricing gap divergence of the major Korean holdcos and opcos amid market carnage. We highlight 26 pair trades...

Logo
509 Views
Share
30 Sep 2022 22:24

Boryung Pharmaceutical (003850 KS): Oncology Portfolio Expansion to Accelerate Growth Momentum

Boryung is expanding oncology portfolio and got approval for in-licensed drug, Zepzelca in Korea. During 2022–2026, oncology segment is expected to...

Logo
380 Views
Share
bearishCelltrion Inc
30 Sep 2022 00:45

Celltrion (068270 KS): Competition Makes US Approval of New Oncology Biosimilar Unappealing

Celltrion got FDA approval for its oncology biosimilar Vegzelma. However, increasing competition and price erosion in the US market, lessen...

Logo
140 Views
Share
x